AdvaMed Statement on the Klomp Nomination

Aliso Viejo, Calif. – Terumo Neuro today announced that it has signed an agreement to acquire Arsenal Medical Inc., a privately held, clinical-stage biomaterials company developing NeoCast™, an investigational next-generation liquid embolic technology for the treatment of chronic subdural hematoma (cSDH). Upon completion, the proposed acquisition would expand Terumo Neuro’s liquid embolic portfolio, advance its strategy to bring differentiated neurovascular technologies to physicians and patients, and support its continued focus on innovations to preserve and restore brain health.

Behind every policy conversation is a patient waiting for access to the care and technology they need. In this edition of AdvaMed in Action, Bobby Patrick explores how collaboration among patient advocates, medtech companies, state partners and policy leaders can help advance patient access and turn shared priorities into meaningful action.

SAN ANTONIO/SALT LAKE CITY, UT — Freyya Inc., a pioneer in women’s pelvic health technology, today announced the oversubscribed close of its pre-seed financing. The financing provides the capital to advance Freyya’s technology through its next regulatory milestones and continue building the foundation for commercialization.

Join industry leaders for the in-depth Medical Device Submissions Workshop series to receive real-world case studies, timely submissions tips, and best practices.

NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) — Emanate Biomedical, Inc., a medical technology company creating a new category of clinician-directed at-home oral care, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for Perio PODS™, a periodontal wound dressing consisting of single-use, patient-matched dental trays preloaded with engineered hydrogel.

Kirsten Tullia shares how AdvaMed Digital Health Tech priorities—from AI and cybersecurity to payment and data—will come to life at #MTC26 in Boston.

Patients should not have to wait years for Medicare coverage of procedures using breakthrough medical technologies the FDA has already authorized for marketing after determining they meet applicable safety and effectiveness standards.

Join Deloitte in this discussion examining how rising consumer expectations, new technology entrants, and evolving provider roles are reshaping how diagnostics manufacturers engage their customers.